Cargando…

Lipoprotein(a) Does Not Predict Thrombotic Events and In-Hospital Outcomes in Patients with COVID-19

The prothrombotic and proinflammatory properties of lipoprotein(a) (Lp(a)) have been hypothesized to play a role in the pathogenesis of severe COVID-19; however, the prognostic impact of Lp(a) on the clinical course of COVID-19 remains controversial. This study aimed to investigate whether Lp(a) may...

Descripción completa

Detalles Bibliográficos
Autores principales: Bianconi, Vanessa, Mannarino, Massimo R., Ramondino, Federica, Fusaro, Jessica, Giglioni, Francesco, Braca, Marco, Ricciutelli, Federica, Lombardini, Rita, Paltriccia, Rita, Greco, Alessia, Lega, Iliana C., Pirro, Matteo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10218794/
https://www.ncbi.nlm.nih.gov/pubmed/37240653
http://dx.doi.org/10.3390/jcm12103543
_version_ 1785048858385973248
author Bianconi, Vanessa
Mannarino, Massimo R.
Ramondino, Federica
Fusaro, Jessica
Giglioni, Francesco
Braca, Marco
Ricciutelli, Federica
Lombardini, Rita
Paltriccia, Rita
Greco, Alessia
Lega, Iliana C.
Pirro, Matteo
author_facet Bianconi, Vanessa
Mannarino, Massimo R.
Ramondino, Federica
Fusaro, Jessica
Giglioni, Francesco
Braca, Marco
Ricciutelli, Federica
Lombardini, Rita
Paltriccia, Rita
Greco, Alessia
Lega, Iliana C.
Pirro, Matteo
author_sort Bianconi, Vanessa
collection PubMed
description The prothrombotic and proinflammatory properties of lipoprotein(a) (Lp(a)) have been hypothesized to play a role in the pathogenesis of severe COVID-19; however, the prognostic impact of Lp(a) on the clinical course of COVID-19 remains controversial. This study aimed to investigate whether Lp(a) may be associated with biomarkers of thrombo-inflammation and the occurrence of thrombotic events or adverse clinical outcomes in patients hospitalized for COVID-19. We consecutively enrolled a cohort of patients hospitalized for COVID-19 and collected blood samples for Lp(a) assessment at hospital admission. A prothrombotic state was evaluated through D-dimer levels, whereas a proinflammatory state was evaluated through C-reactive protein (CRP), procalcitonin, and white blood cell (WBC) levels. Thrombotic events were marked by the diagnosis of deep or superficial vein thrombosis (DVT or SVT), pulmonary embolism (PE), stroke, transient ischemic attack (TIA), acute coronary syndrome (ACS), and critical limb ischemia (CLI). The composite clinical end point of intensive care unit (ICU) admission/in-hospital death was used to evaluate adverse clinical outcomes. Among 564 patients (290 (51%) men, mean age of 74 ± 17 years) the median Lp(a) value at hospital admission was 13 (10–27) mg/dL. During hospitalization, 64 (11%) patients were diagnosed with at least one thrombotic event and 83 (15%) patients met the composite clinical end point. Lp(a), as either a continuous or categorical variable, was not associated with D-dimer, CRP, procalcitonin, and WBC levels (p > 0.05 for all correlation analyses). In addition, Lp(a) was not associated with a risk of thrombotic events (p > 0.05 for multi-adjusted odds ratios) nor with a risk of adverse clinical outcomes (p > 0.05 for multi-adjusted hazard ratios). In conclusion, Lp(a) does not influence biomarkers of plasma thrombotic activity and systemic inflammation nor has any impact on thrombotic events and adverse clinical outcomes in patients hospitalized for COVID-19.
format Online
Article
Text
id pubmed-10218794
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-102187942023-05-27 Lipoprotein(a) Does Not Predict Thrombotic Events and In-Hospital Outcomes in Patients with COVID-19 Bianconi, Vanessa Mannarino, Massimo R. Ramondino, Federica Fusaro, Jessica Giglioni, Francesco Braca, Marco Ricciutelli, Federica Lombardini, Rita Paltriccia, Rita Greco, Alessia Lega, Iliana C. Pirro, Matteo J Clin Med Article The prothrombotic and proinflammatory properties of lipoprotein(a) (Lp(a)) have been hypothesized to play a role in the pathogenesis of severe COVID-19; however, the prognostic impact of Lp(a) on the clinical course of COVID-19 remains controversial. This study aimed to investigate whether Lp(a) may be associated with biomarkers of thrombo-inflammation and the occurrence of thrombotic events or adverse clinical outcomes in patients hospitalized for COVID-19. We consecutively enrolled a cohort of patients hospitalized for COVID-19 and collected blood samples for Lp(a) assessment at hospital admission. A prothrombotic state was evaluated through D-dimer levels, whereas a proinflammatory state was evaluated through C-reactive protein (CRP), procalcitonin, and white blood cell (WBC) levels. Thrombotic events were marked by the diagnosis of deep or superficial vein thrombosis (DVT or SVT), pulmonary embolism (PE), stroke, transient ischemic attack (TIA), acute coronary syndrome (ACS), and critical limb ischemia (CLI). The composite clinical end point of intensive care unit (ICU) admission/in-hospital death was used to evaluate adverse clinical outcomes. Among 564 patients (290 (51%) men, mean age of 74 ± 17 years) the median Lp(a) value at hospital admission was 13 (10–27) mg/dL. During hospitalization, 64 (11%) patients were diagnosed with at least one thrombotic event and 83 (15%) patients met the composite clinical end point. Lp(a), as either a continuous or categorical variable, was not associated with D-dimer, CRP, procalcitonin, and WBC levels (p > 0.05 for all correlation analyses). In addition, Lp(a) was not associated with a risk of thrombotic events (p > 0.05 for multi-adjusted odds ratios) nor with a risk of adverse clinical outcomes (p > 0.05 for multi-adjusted hazard ratios). In conclusion, Lp(a) does not influence biomarkers of plasma thrombotic activity and systemic inflammation nor has any impact on thrombotic events and adverse clinical outcomes in patients hospitalized for COVID-19. MDPI 2023-05-18 /pmc/articles/PMC10218794/ /pubmed/37240653 http://dx.doi.org/10.3390/jcm12103543 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Bianconi, Vanessa
Mannarino, Massimo R.
Ramondino, Federica
Fusaro, Jessica
Giglioni, Francesco
Braca, Marco
Ricciutelli, Federica
Lombardini, Rita
Paltriccia, Rita
Greco, Alessia
Lega, Iliana C.
Pirro, Matteo
Lipoprotein(a) Does Not Predict Thrombotic Events and In-Hospital Outcomes in Patients with COVID-19
title Lipoprotein(a) Does Not Predict Thrombotic Events and In-Hospital Outcomes in Patients with COVID-19
title_full Lipoprotein(a) Does Not Predict Thrombotic Events and In-Hospital Outcomes in Patients with COVID-19
title_fullStr Lipoprotein(a) Does Not Predict Thrombotic Events and In-Hospital Outcomes in Patients with COVID-19
title_full_unstemmed Lipoprotein(a) Does Not Predict Thrombotic Events and In-Hospital Outcomes in Patients with COVID-19
title_short Lipoprotein(a) Does Not Predict Thrombotic Events and In-Hospital Outcomes in Patients with COVID-19
title_sort lipoprotein(a) does not predict thrombotic events and in-hospital outcomes in patients with covid-19
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10218794/
https://www.ncbi.nlm.nih.gov/pubmed/37240653
http://dx.doi.org/10.3390/jcm12103543
work_keys_str_mv AT bianconivanessa lipoproteinadoesnotpredictthromboticeventsandinhospitaloutcomesinpatientswithcovid19
AT mannarinomassimor lipoproteinadoesnotpredictthromboticeventsandinhospitaloutcomesinpatientswithcovid19
AT ramondinofederica lipoproteinadoesnotpredictthromboticeventsandinhospitaloutcomesinpatientswithcovid19
AT fusarojessica lipoproteinadoesnotpredictthromboticeventsandinhospitaloutcomesinpatientswithcovid19
AT giglionifrancesco lipoproteinadoesnotpredictthromboticeventsandinhospitaloutcomesinpatientswithcovid19
AT bracamarco lipoproteinadoesnotpredictthromboticeventsandinhospitaloutcomesinpatientswithcovid19
AT ricciutellifederica lipoproteinadoesnotpredictthromboticeventsandinhospitaloutcomesinpatientswithcovid19
AT lombardinirita lipoproteinadoesnotpredictthromboticeventsandinhospitaloutcomesinpatientswithcovid19
AT paltricciarita lipoproteinadoesnotpredictthromboticeventsandinhospitaloutcomesinpatientswithcovid19
AT grecoalessia lipoproteinadoesnotpredictthromboticeventsandinhospitaloutcomesinpatientswithcovid19
AT legailianac lipoproteinadoesnotpredictthromboticeventsandinhospitaloutcomesinpatientswithcovid19
AT pirromatteo lipoproteinadoesnotpredictthromboticeventsandinhospitaloutcomesinpatientswithcovid19